Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry. Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positions in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
The MMRF's Latest Interim Analysis from the CoMMpass Study and What it Means for Myleoma Patients
The MMRF's Latest Interim Analysis from the CoMMpass Study and What it Means for Myleoma Patients
Whether you are a myeloma patient, or a caregiver, you know how valuable the support of a community can be. By participating, you are providing valuable data and insights to the patient community by sharing your experiences and offering support.
Similarly, when you participate in studies, you are providing valuable data and insights to researchers who are helping to find a cure for myeloma. When you participate in the MMRF’s CoMMpass Study℠ (CoMMpass), you’re helping us create a global community of patients, clinicians and researchers who are working together to extend the lives of myeloma patients everywhere.
Many of you have probably heard of CoMMpass before – it is a research study involving patients with newly diagnosed active multiple myeloma. The goal is to map the genomic profile of up to 1,000 myeloma patients at diagnosis, and at multiple points throughout the course of the disease, helping researchers to understand how each patient responds to different treatments over time.
We strongly believe that providing researchers and clinicians around the world with access to data from CoMMpass will revolutionize the way multiple myeloma is treated.
Every six months, we provide researchers and clinicians with updated data through our Researcher Gateway. Similar to the Community Gateway, this is an online portal that allows researchers and clinicians to easily exchange and share data with one another.
The fifth data release – or interim analysis as you may see it referred to – occurred in March 2015. Genomic data from 190 participants was made available on the Researcher Gateway. This data will help researchers to identify new genomic changes in myeloma throughout the course of the disease.
The data also included the first comparisons of molecular changes that occurred at diagnosis and at points of progression from the same patient. This means that researchers will be able to better understand how myeloma changes over time in a specific patient, allowing healthcare professionals to adjust the course of treatment based on the patient’s genetic profile.
This is just a start and we are excited to continually provide the research community with new data to better understand how different patients respond to specific therapies. We hope to use this data to help develop personalized treatments for myeloma that target the underlying cause of the disease –meaning better care for you.
Want to learn more about CoMMpass? Contact one of our nurse specialists at 866-603-6628.
